Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, March 21, 2025 /PRNewswir ...

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud that affected investors between June 7, 2024, and February 25, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the launch and growth potential of its drug Rytelo (imetelstat), downplaying risks associated with monitoring requirements and competition [2] - Following the announcement of Geron's fourth quarter financial results for fiscal 2024 on February 26, 2025, which revealed that Rytelo's growth had flattened, the company's stock price dropped significantly from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=137097&from=4CLASS PERIOD: June 7, 2024 to ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between June 7, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submission ...

Geron Corp (NASDAQ: GERN ) is a venerable, long-in-development-hell biotech working on the commercialization and development of the lone telomerase inhibitor approved for any indication. The year 2024 saw the first sales of their agent Rytelo in the space of lower-riskI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do y ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about its revenue outlook and growth potential [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron provided false and misleading information to investors, creating an overly optimistic view of the projected revenue and growth related to the launch of Rytelo [2]. - It is alleged that Geron did not disclose that Rytelo lacked necessary patient awareness, which hindered the company's ability to meet the claimed significant unmet need for the drug [2]. Group 2: Investor Participation - Shareholders who purchased Geron's securities between June 7, 2024, and February 25, 2025, are encouraged to contact the DJS Law Group to participate in the class action lawsuit before May 12, 2025 [1][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Geron Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its revenue outlook and product performance [1][5]. Group 1: Class Action Details - The class action is filed for securities purchased between June 7, 2024, and February 25, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [1][2]. - Interested parties can join the class action by contacting Rosen Law Firm, with a deadline to serve as lead plaintiff set for May 12, 2025 [3][6]. Group 2: Allegations Against Geron Corporation - The lawsuit alleges that Geron Corporation made false and misleading statements regarding its product Rytelo, creating an inaccurate perception of its market potential and revenue growth while downplaying risks associated with seasonality and competition [5]. - The claims suggest that the actual market performance of Rytelo was significantly below expectations, with challenges in market penetration and competition impacting patient starts more than previously indicated [5].

Core Insights - A class action has been filed against Geron Corporation on behalf of investors who acquired its securities between June 7, 2024, and February 25, 2025, due to alleged misleading information regarding the launch and growth potential of its product Rytelo [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancer treatment, with its primary product being a telomerase inhibitor named imetelstat, marketed as Rytelo [1]. Allegations - The complaint claims that Geron misled investors by presenting overly optimistic reports about Rytelo's launch success and growth potential, failing to disclose significant factors such as seasonality, competition, and the burden of monitoring that affected patient starts [2]. - It is alleged that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients and those outside academic settings [2]. Financial Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had stagnated. The company attributed this to seasonality, competition, lack of awareness, and monitoring requirements [3]. - Following this announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [3].